CGEN - Compugen Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Compugen Ltd.

Building D
26 Harokmim Street Azrieli Center
Holon 5885849
Israel
972 3 765 8585
http://www.cgen.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees89

Key Executives

NameTitlePayExercisedYear Born
Dr. Anat Cohen-DayagCEO, Pres & Director672.39kN/A1967
Mr. Ari KrashinChief Financial & Operating Officer361.46kN/A1973
Dr. John J. Hunter Ph.D.Chief Scientific Officer496.03kN/A1963
Mr. Kirk A. ChristoffersenSr. VP of Corp. & Bus. Devel.549.34kN/A1969
Dr. Henry Adewoye M.D.Chief Medical Officer564.69kN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets, including T cell immune checkpoints and other early-stage immuno-oncology programs focusing on myeloid target. Its product pipeline consists of COM701, a therapeutic antibody that is in phase I clinical trials for PVRIG; BAY 1905254, a therapeutic antibody that is in phase I clinical trials for ILDR2; and COM902, a therapeutic immuno-oncology antibody for TIGIT program. Compugen Ltd. has a collaboration agreement with Bristol-Myers Squibb Company to evaluate the safety of COM701 in combination with Bristol-Myers Squibb's programmed death-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and license agreement with MedImmune Limited for the development of bi-specific and multi-specific immuno-oncology antibody products. The company was incorporated in 1993 and is headquartered in Holon, Israel.

Corporate Governance

Compugen Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.